Clinical Trial Update: PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing panitumumab plus mFOLFOX6 to bevacizumab plus mFOLFOX6 as first-line therapy for metastatic colorectal cancer with wild-type KRAS; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• MFOLFOX6
• Panitumumab (panitumumab)

Snippet

Sponsor: Amgen | Conditions: Colon Cancer, Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-08-06